Skip to content

Journal · Neurology · Updated 21 November 2026

Neurology and Therapy

Read Neurology and Therapy articles on DeepDyve. No university library needed.

Neurology and Therapy has published since 2012 and covers treatments for neurological disease, from Parkinson’s disease infusions and gene therapy for Duchenne muscular dystrophy to myasthenia gravis, stroke and neuromyelitis optica. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Neurology and Therapy
Journal cover

Neurology and Therapy at a glance

Full title
Neurology and Therapy
Abbreviation (NLM)
Neurol Ther
Publisher
Springer Nature
Print ISSN
2193-8253
Online ISSN (eISSN)
2193-6536
First published
2012
Access model
Open access since 2012

Ways to access Neurology and Therapy

All of the articles Neurology and Therapy published from January 1 to November 20, 2026 are open access and free to read. For older articles, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 100% of Neurology and Therapy articles published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Neurology and Therapy. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Neurology and Therapy articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Neurology and Therapy’s 2025 Journal Impact Factor is 4.7, and its 5-year Impact Factor is 5.4.

4.7

Journal Impact Factor (2025)

5.4

5-year Impact Factor (2025)

1.1M

Downloads (2025)

Source: journal metrics on the Neurology and Therapy homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Neurology and Therapy research worth reading

Published January to May 2026. Summaries describe what the authors report.

  1. Open accessParkinson’s disease · Infusion therapy

    Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson’s Disease: ROSSINI Study 6-Month Interim Results

    In 6-month interim results from the ROSSINI real-world study of 105 patients with advanced Parkinson’s disease, the authors report that foslevodopa/foscarbidopa cut OFF time by 2.8 h, with a safety profile consistent with clinical trials.

    Jost et al. · Neurology and Therapy, published online May 7, 2026 · DOI 10.1007/s40120-026-00948-6

  2. Open accessDuchenne muscular dystrophy · Gene therapy

    Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial

    Reporting 2-year EMBARK results, the authors find that ambulatory boys aged 4 to < 8 years given delandistrogene moxeparvovec showed significant benefit over a matched external control on functional outcomes, with no new safety signals between week 52 and week 104.

    Mendell et al. · Neurology and Therapy, published online January 10, 2026 · DOI 10.1007/s40120-025-00879-8

  3. Open accessMyasthenia gravis · Immunotherapy

    Efgartigimod in Patients with Generalized Myasthenia Gravis Refractory or Intolerant to IVIg

    In thirteen AChR-positive generalized myasthenia gravis patients who failed or could not tolerate IVIg, the authors report that one cycle of efgartigimod improved MG-ADL and QMG scores, with responder rates of 84.6% and 69.2%.

    D’Amico et al. · Neurology and Therapy, published online April 1, 2026 · DOI 10.1007/s40120-026-00923-1

  4. Open accessIschemic stroke · Biomarkers

    Venous Blood Cell Ratios as Predictors of Reperfusion Outcomes in Ischemic Stroke: A Systematic Review and Meta-analysis

    Pooling fifty-seven studies with 17,394 patients, the authors report that a higher pre-treatment neutrophil-to-lymphocyte ratio predicted poor outcome after both mechanical thrombectomy and intravenous thrombolysis, while other blood cell ratios gave variable or null results.

    Szegedi et al. · Neurology and Therapy, published online January 13, 2026 · DOI 10.1007/s40120-025-00881-0

  5. Open accessNeuromyelitis optica · Clinical trial

    Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial

    In a phase Ib trial of obinutuzumab β in 11 AQP4-IgG-positive patients with neuromyelitis optica spectrum disorder, the authors report manageable safety, a 2-year relapse-free rate of 81.8% and an 87.7% drop in annualized relapse rate.

    Wu et al. · Neurology and Therapy, published online May 24, 2026 · DOI 10.1007/s40120-026-00960-w

See every Neurology and Therapy article on DeepDyve

Questions about Neurology and Therapy

How can I read Neurology and Therapy articles without a subscription?

100% of Neurology and Therapy articles published from January 1 to November 20, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Neurology and Therapy articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Neurology and Therapy?

Neurology and Therapy’s NLM (PubMed) abbreviation is Neurol Ther.

What is the ISSN of Neurology and Therapy?

The print ISSN is 2193-8253 and the online ISSN is 2193-6536.

What is the impact factor of Neurology and Therapy?

Neurology and Therapy’s Journal Impact Factor is 4.7 (2025), and its 5-year Impact Factor is 5.4, according to Springer Nature’s published metrics.

Is Neurology and Therapy open access?

Yes. Neurology and Therapy has published open access since 2012: 195 of the 195 articles it published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref.

Neurology and Therapy articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.

Start reading Neurology and Therapy today

One month free, then less than $2 a day. Neurology and Therapy, plus millions of articles from thousands of journals.

Start free month

Like this: